Turner, N. C., Jhaveri, K. L., Bardia, A., Niikura, N., Bellet, M., Barrios, C. H., Diéras, V., Im, S., Mueller, V., Song, E., Rodriguez, J. L. M., Bondarenko, I., Mardones, M. A., Chang, C., Louka, M., Craft, M., Pérez-Moreno, P. D., Patre, M., Loi, S. (2026). Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA BC trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba1006